[
  {
    "ts": null,
    "headline": "Eli Lilly Expands Beyond GLP 1s With Orna Deal And Nvidia Alliance",
    "summary": "Eli Lilly (NYSE:LLY) has agreed to acquire Orna Therapeutics, moving into engineered RNA medicines for autoimmune diseases and other conditions. The company has entered a US$1b artificial intelligence drug discovery collaboration with Nvidia to support its research pipeline. Eli Lilly is preparing for a potential launch of its oral weight loss drug orforglipron, with an FDA decision expected in the near term and pre-launch inventory already being built. Eli Lilly, long associated with...",
    "url": "https://finnhub.io/api/news?id=692b5e38393f413faf6c1314fe9f80030938491755f2ceb9ca88767a54127b92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771085200,
      "headline": "Eli Lilly Expands Beyond GLP 1s With Orna Deal And Nvidia Alliance",
      "id": 139098365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) has agreed to acquire Orna Therapeutics, moving into engineered RNA medicines for autoimmune diseases and other conditions. The company has entered a US$1b artificial intelligence drug discovery collaboration with Nvidia to support its research pipeline. Eli Lilly is preparing for a potential launch of its oral weight loss drug orforglipron, with an FDA decision expected in the near term and pre-launch inventory already being built. Eli Lilly, long associated with...",
      "url": "https://finnhub.io/api/news?id=692b5e38393f413faf6c1314fe9f80030938491755f2ceb9ca88767a54127b92"
    }
  },
  {
    "ts": null,
    "headline": "Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference",
    "summary": "Foghorn Therapeutics (NASDAQ:FHTX) President and CEO Adrian Gottschalk said the company was built around the idea that chromatin regulation—and specifically the BAF (SWI/SNF) chromatin remodeling complex—represents a broad and clinically relevant set of oncology targets that have historically been d",
    "url": "https://finnhub.io/api/news?id=48f07fac5e59e54dbfa8a340d150f3f3b5d934f047c4d20b70412dd295dfceb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771027411,
      "headline": "Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference",
      "id": 139092055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Foghorn Therapeutics (NASDAQ:FHTX) President and CEO Adrian Gottschalk said the company was built around the idea that chromatin regulation—and specifically the BAF (SWI/SNF) chromatin remodeling complex—represents a broad and clinically relevant set of oncology targets that have historically been d",
      "url": "https://finnhub.io/api/news?id=48f07fac5e59e54dbfa8a340d150f3f3b5d934f047c4d20b70412dd295dfceb3"
    }
  }
]